MEI Pharma, Inc. (NASDAQ: MEIP) saw its shares make a solid gain on Thursday after the company received a crucial upgrade from Oppenheimer. Most analysts only issue price targets that are within a range of 5% to 25% for stocks, but this upgrade absolutely blows these small calls out of the water.
Oppenheimer initiated MEI Pharma with a Buy rating and a $6.50 price target, implying an upside of 289% from the most recent closing price of $1.67.
MEI Pharma, a development-stage biotechnology company working in epigenetics, the PI3K pathway and cancer metabolism, has three experimental compounds in development.
The first compound, Pracinostat, is being developed with Helsinn Group for the treatment of AML and other potential indications. The second, MEI-401, is being evaluated in relapsed or refractory chronic lymphocytic leukemia (CLL) and follicular lymphoma. MEI Pharma’s third compound is ME-344 and is the subject of an investigator-sponsored study in HER2-negative breast cancer as an exploration in combination with a VEGF or TKI inhibitor.
Oppenheimer noted in its report:
We estimate that two of these compounds, Pracinostat and MEI-401, could result in sales in calendar year 2022. We are initiating coverage of MEI Pharma with an Outperform rating and $6.50 target price.
Another analyst weighed in on the stock yesterday, but outside of that no calls have been issued since last year. Cann reiterated an Outperform rating.
Excluding Thursday’s move, MEI Pharma has outperformed the broad markets and risen 16% year to date.
Shares of MEI Pharma were last trading up 17% at $1.95, with a 52-week trading range of $1.23 to $2.28.
Are You Still Paying With a Debit Card?
The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.
Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!
Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!
Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.